A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)
Clinical trial NCT05176639 · COMPLETED
Trial details
- NCT number
- NCT05176639
- Sponsor
- Viridian Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-16
- Primary completion
- 2024-07-15
- Enrollment
- 113
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.